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ABSTRACT The tissue distribution of CD4 lymphocytes
in normal C57/BL mice and CD4 knockout mice was deter-
mined by biodistribution measurements and gamma camera
imaging with an 'llIn- labeled rat IgG2b monoclonal antibody
directed against the murine CD-4 antigen. In normal mice,
high concentrations of antibody accumulated in the spleen
and lymph nodes. At 45 hr after injection, the concentrations
of radiolabel in the spleen and lymph nodes of normal mice
were 10- to 20-fold greater than in the corresponding tissues
of the CD4 knockout mice and nonlymphoid tissues of both
types of mice. At 24 and 45 hr, gamma camera images showed
high concentrations of radiolabeled antibody in lymph nodes
and spleen of normal but not knockout mice. These results
indicate that radioimmunoscintigraphy with "'In-anti-CD4 is
an excellent method for studying tissue distribution of CD4
lymphocytes in mice. Using an equivalent anti-human CD4
antibody, this method might be useful for studying the patho-
physiology of conditions in which these cells play a critical role
and for monitoring therapies for these disorders.
From the early days of the human immunodeficiency virus
(HIV) epidemic, it has been apparent that the CD4-positive
lymphocyte is the major target of this virus (1). Although HIV
is capable of infecting other cells such as monocytes (2-4),
follicular dendritic cells (5), epidermal Langerhans cells (6),
alveolar macrophages (7), and glial cells within the central
nervous system (8-10), the CD4-positive lymphocytes bear the
brunt of viral attack. Thus, enumeration of CD4 cells in the
peripheral blood has been the most widely used test for
monitoring HIV-induced immune dysfunction, as well as
serving as a surrogate marker for evaluating anti-viral drug
efficacy (11).
Unfortunately, this simple test, the "peripheral CD4 count,"
has not proven as useful for these purposes as had been
originally hoped. It is now recognized that major functional
alterations in immunity may be unrecognized by CD4 cell
enumeration alone: (i) there is considerable day-to-day vari-
ability in CD4 counts within a given individual; (ii) CD4 counts
do not provide any information about lymphocyte function;
(iii) the peripheral blood compartment comprises only 2-5%
of the total body lymphoid tissue, and important changes in
CD4 cell trafficking and distribution may not be represented
by measurements that sample only the peripheral blood com-
partment; and (iv) most importantly, serial determination of
CD4 levels as a marker for anti-viral efficacy has proven to be
a disappointment-i.e., maintenance or elevations in CD4 cell
counts achieved in association with antiviral therapy have not
been predictive of prolonged life or decreased incidence of
opportunistic infection (1, 11, 12).
Thus, there remains a compelling need for a noninvasive test
for assessing the totality of CD4 cell distribution and traffick-
ing throughout the body. Such a technique would be invaluable
both for evaluating individual patients with HIV infection and
as an experimental tool in the assessment of candidate ther-
apies for this disease. In addition, it would be of interest in the
evaluation of patients with such autoimmune processes as
rheumatoid arthritis and multiple sclerosis, in whom immu-
nomodulating therapy has much to offer. We report here the
initial evaluation, in a murine model, of the use of a specific
radiolabeled anti-CD4 mAb and serial gamma camera imaging
to delineate the tissue distribution of CD4-positive lymphocytes.
MATERIALS AND METHODS
Preparation of "'In-Labeled Antibody. GK1.5, a rat IgG2b
noncytotoxic mAb directed against the murine CD-4 antigen
(13), was graciously provided as crude ascites by Hugh Auch-
incloss (Transplant Unit, Massachusetts General Hospital).
Rat IgG was isolated from the ascites by a two-step method of
ammonium sulfate precipitation, followed by protein G puri-
fication, as described (14). HPLC analysis of the resulting
protein solution using a size exclusion column revealed a single
protein peak that eluted with a retention time corresponding
to monomeric IgG.
This antibody was conjugated with diethylenetriamine pen-
taacetic acid (DTPA) by the carboxy-carbonic anhydride
method (15,16). The DTPA-antibody conjugate was diluted to
2 mg of protein per millimeter (in 0.9% sodium chloride for
injection; U.S. Pharmacopeia) and sterilized by membrane
filtration. Aliquots of 0.1 ml were transferred aseptically to
2-ml sterile and pyrogen-free vials and stored at 4°C for
subsequent labeling with "'1In.
The DTPA-antibody conjugate was radiolabeled with ster-
ile, pyrogen-free "'1In chloride as follows: GK1.5-DTPA (50
,ul, 100 jig) was mixed with 50 ,lI of 1 N sodium citrate (pH 5.3)
and 5 ,ul (-3 mCi; 1 Ci = 37 GBq) of "tIn chloride (NEZ 304,
DuPont/NEN) was added, The solution was incubated at room
temperature for 4 hr and the radiolabeled protein was sepa-
rated on a 1 x 30 cm size-exclusion column (Sephadex
G-25-80) eluted with 0.9% sodium chloride.
CD4 Binding Assay. DTPA-conjugated GK1.5 was tested in
vitro to confirm that it had not lost its ability to bind with high
specificity to CD4 expressed on murine splenocytes. Spleno-
cytes harvested from C57/BL mice were incubated with
DTPA-GK1.5 (5 ,ug/ml) or a control isotype matched anti-
body directed against murine CD4 (clone YTS 191.1). The
splenocyte-antibody complexes were then incubated with
anti-Rat IgG2b antibody conjugated with fluorescein isothio-
cyanate (PharMingen) and analyzed by fluorescence activated
flow cytometry (FACScan, Becton Dickinson).
Flow cytometric analysis indicated that an equivalent num-
ber of CD4 cells, as a fraction of total splenocytes, could be
detected with both DTPA-GK1.5 and the unmodified anti-
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body. Furthermore, when bound to CD4+ splenocytes, DT-
PA-GK1.5 was detected by anti-Rat IgG2b-fluorescein isothio-
cyanate with equal or greater fluorescence intensity compared
with the unmodified antibody.
Imaging and Biodistribution Studies. Groups of normal
C57/BL and CD-4 knockout mice weighing -25 g (The
Jackson Laboratory) were used in these studies. All radio-
phramaceuticals were injected intravenously via the tail vein
and biodistribution/gamma camera imaging were performed
as described below.
Effect of Specific Activity of "'In-Labeled GK1.5 on Bio-
distribution and Gamma Camera Imaging. Six normal
C57/BL mice were injected with 10 ,uCi of 11'In-labeled GK1.5
containing 0.4, 9.7, or 99.7 ,ug of unlabeled antibody protein.
At 24 hr post-injection the animals were sacrificed by anes-
thesia overdose, and the organs removed for biodistribution
studies. Samples of blood, liver, spleen, thymus, mesentery,
kidney, bone, and lymph nodes were weighed and radioactivity
was measured with a well-type gamma counter (LBK model
1282 Wallae Oy, Finland). To correct for radioactive decay,
aliquots of the injected doses were counted simultaneously.
The results were expressed as percentage injected dose per gram
(% ID/g).
Three additional normal C57/BL mice were injected with
100 ,uCi of 11'In-labeled GK1.5 containing 13, 22, or 112 ,tg of
unlabeled antibody protein. At 24 hr post-injection the animals
were anesthetized with ether and whole body scintigrams were
acquired using a large field of view gamma camera equipped
with a pin-hole collimator containing a 3-mm insert and
interfaced to a dedicated computer system (Technicare 410/
Technicare 560, Solon, OH). Images were recorded for a
preset time of 5 min per view with windows centered on the 174
and 247 KeV photopeaks of "'In.
Effect of CD4 Gene Expression on Imaging and Biodistri-
bution. Normal C57/BL and CD-4 knockout mice (n =
6/group) were injected with 100 ,tCi of "'In-labeled GK1.5
containing 5.4 ,tg of protein, and gamma camera imaging/
biodistribution measurements were performed as described
above. In this study, the animals were imaged at 2.5, 24, and
45 hr after injection. In one additional normal mouse imaging
was performed 60 hr after injection.
Statistical Methods. The results of all experiments were
evaluated by analysis of variance using a linear model in which
tissue and antibody dose or CD4 status (normal C57/BL or
CD4 knockout) were the classification variables (% ID/g =
tissue + antibody dose + tissue * antibody dose or %ID/g =
tissue + CD4 status + tissue * CD4 status). Post hoc comparisons
of individual means were performed by Duncan's new multiple
range test (17). All results were expressed as mean ± SEM.
RESULTS
To examine whether a radiolabeled anti-CD4 antibody will
home to antigen-containing cells in an animal's body, we
injected 100 ,uCi of "'In-labeled GK1.5 mAb into normal
mice. Serial gamma camera images were acquired 2.5, 24, 45,
and 60 hr later (Fig. 1). The earliest image showed significant
concentration of radioactivity in the blood pool, diffuse dis-
tribution of radioactivity throughout the rest of the body, and
low levels of focal accumulation in axillary and inguinal lymph
nodes and spleen. In the 24-hr image, clear focal accumulation
of radiolabeled antibody was observed in cervical, axillary, and
inguinal lymph nodes and spleen. This focal accumulation
intensified in the 45-hr image and remained unchanged to 60
hr. Gamma camera images were then acquired 24 hr after
injection of radiolabeled antibody at three different specific
activities (Fig. 2). The highest specific activity antibody gave
clear focal accumulation of radioactivity in the spleen and
lymph nodes. In the intermediate specific activity image, the
focal localization of radioactivity was significantly reduced,
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FIG. 1. Serial gamma camera images of a normal mouse acquired
2.5, 24, 45, and 60 hr after injection of 100 ,uCi of "'In-labeled GK1.5
anti-CD4 mAb.
and it was totally abolished in the low specific activity image.
Thus, competitive inhibition of the localization of labeled
antibody by increasing concentrations of unlabeled antibody
was evident.
To determine whether the focal accumulations of radioac-
tivity were due to binding of antibody to surface CD4 on cells,
we compared images acquired from normal and CD4-'- mice
(Fig. 3). At 24 and 45 hr after injection there was a highly
localized antibody in the lymph nodes and spleen of the normal
animals that was not evident in the knockout mice.
Having seen the focal accumulations visually we turned to
biodistribution measurements to examine the binding more
quantitatively. These were performed 24 hr after injection of
the "'In-labeled anti-CD4 mAb into normal mice and dem-
onstrated particularly high concentrations of antibody associ-
ated radioactivity in the spleen and lymph nodes. When increas-
ing quantities of unlabeled antibodywere added to a fixed amount
of radiolabeled antibody (thus decreasing specific activity) there
was a dose-dependent decrease in the amount of radiolabeled
antibody that localized in the spleen (Fig. 4). In the other tissues,
however, the results were variable, suggesting that the CD4 may
not be saturated by these amounts of antibody.
When studies were performed 45 hr after the injection of the
radiolabeled mAb in normal and CD4 knockout mice, a
striking difference in biodistribution was observed (Fig. 5). In
the normal mice, the concentrations of radiolabel in the spleen
and lymph nodes was 10- to 20-fold greater than in the
corresponding tissues of the CD4 knockout mice (P < 0.0001)
and 10- to 20-fold greater than the concentrations achieved in
nonlymphoid tissues of both normal and CD4 knockout mice
(P < 0.0001). Similar but smaller effects were observed in
mesentery (P < 0.01) and bone (P < 0.05). In contrast, higher
concentrations of antibody were observed in blood of CD4
knockout mice (P < 0.01). In liver and thymus, antibody
accumulation was similar in normal and CD4 knockout mice
(P = not significant).
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FIG. 2. Gamma camera images demonstrating the effect of specific
activity of "'In-labeled GK1.5 anti-CD4 mAb on localization in spleen
and lymph nodes.
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FIG. 3. Serial gamma camera images acquired 24 and 45 hr after
injection of "'In-labeled GK1.5 anti-CD4 mAb in normal C57/BL
mice and syngenetic CD4 knockout mice.
These two biodistribution studies suggest that the localiza-
tion of the radiolabeled CD4 antibody in lymphoid tissue of the
mouse is mediated by specific, rather than nonspecific, mech-
anisms. Furthermore, the differences in tissue accumulation of
radiolabeled antibody were clearly sufficient to permit nonin-
vasive imaging of the distribution of this antibody.
DISCUSSION
These experiments were designed to evaluate the feasibility of
using a radiolabled mAb to measure the tissue distribution and,
potentially, the trafficking of CD4-positive lymphocytes. The
results suggest that specific localization of the radiolabeled
antibody occurs in the spleen and lymph nodes. Specificity is
shown by two sets of experiments: (i) blockade of specific
localization by increasing doses of unlabeled antibody that is
consistent with competition for a limited number of specific
antigenic sites and (ii) failure of localization of the radiola-
beled antibody to lymphoid tissue in CD4 knockout mice. In
addition, a nonspecific mAb labeled with indium-111 in iden-
tical fashion failed to image the spleen and lymph nodes (18).
The effect of an increasing dose of unlabeled antibody on
localization of "'In-GK1.5 was observed in both the biodis-
tribution and imaging experiments. However, the degree of
blockade was greater in the biodistribution studies. This was
probably due to the relatively low specific activity of the
product of radiolabeling and the requirement of larger
amounts of radioactivity for imaging. Due to these constraints,
even the highest specific activity preparation used in the
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FIG. 4. Effect of specific activity on the biodistribution of "l'In-
labeled GK1.5 anti-CD4 mAb in normal C57/BL mice 24 hr after
injection. Each value is the mean ± SEM for six animals. **, P < 0.01;
*, P < 0.05.
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FIG. 5. Biodistribution of "11In-labeled GK1.5 anti-CD4 mAb (5.7
Ag/100 OCi) in normal C57/BL mice and syngenetic CD4 knockout
mice 45 hr after injection. Each value is the mean ± SEM for six
animals. ***, P < 0.001; **, P < 0.01; *, P < 0.05.
imaging studies (13 ,ug per mouse; Fig. 2) contained a mass of
unlabeled antibody sufficient to produce considerable block-
ade. Although the effect of an increasing amount of unlabeled
antibody in the injected dose resulted in a monotonic reduction
in accumulation of radioactivity in the spleen, a biphasic effect
was observed in the lymph nodes. This could be related to
differences in the concentration of antigenic sites in the two
tissues and mass-action considerations.
The observation that the specific localization that occurs is of
an extent sufficient to permit imaging is important, because it
provides a noninvasive approach for evaluating serially the dis-
tribution of CD4-positive lymphocytes during the course of
disease or its therapy. Thus, experimentally, this approach might
be useful for studying murine models ofautoimmune disease such
as allergic encephalomyelitis, collagen induced arthritis, and the
spontaneously occurring lupus-like syndromes of NZB/NZW
mice, as well as candidate therapies for these conditions.
Clearly, the more important implication of these results is the
potential application of the approach to the study of humans.
There is considerable precedent for studying the trafficking in
leukocyte populations in vivo in humans by nuclear medicine
techniques. In particular, the migration of polymorphonuclear
leukocytes from peripheral blood to sites of focal infection has
been applied as a diagnostic test and two different approaches
have shown clinical utility. With the first method, blood is drawn
from the individual, polymorphonuclear leukocytes are isolated
and radiolabeled with either "'In or 99mTc, and the labeled cells
are re-infused (19-21). In the second method, a mAb specific for
a polymorphonuclear leukocyte cell surface antigen is radio-
labeled with either "'In or 99mTc, and infused into the subject,
with subsequent in vivo labeling of circulating and tissue bound
polymorphonuclear leukocytes (22, 23). With both techniques,
the radiolabeled cells are followed by serial gamma camera
imaging (typically over 12-48 hr post-infusion), to detect focal
accumulation at the site of infection (19-23).
The imaging and biodistribution studies reported here fur-
ther extend this approach. Our results indicate that a specific,
high-affinity mAb directed against a lymphocyte cell surface
marker can be used for in vivo studies of the tissue distribution
and trafficking of particular lymphocyte subpopulations-in
this case CD4-positive lymphocytes. In addition to the semi-
quantitative nature of the imaging data that is obtained, the
noninvasive character of this approach provides an opportu-
nity for serial studies to assess disease progression and the
response to therapy. The application of this technique for the
serial study of HIV infection and a variety of autoimmune
conditions in humans is obvious. Since only tracer amounts of
antibody are required for imaging, these studies should not
produce significant perturbations of the immune system.
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